Opinion

Video

Treatment Strategies for NSCLC with Non-Actionable Mutations

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.

  1. Please provide a brief overview of the landscape surrounding first-line treatment of NSCLC.
    1. What treatment options are available?
    2. How do treatment approaches differ between patients with actionable vs non-actionable mutations?
  2. Briefly outline your general treatment approach for NSCLC with non-actionable mutations. (Singh, et al. J Clin Oncol, 2022)
    1. What is the role of immunotherapy (IO) in this treatment space?
    2. What factors are most critical for guiding treatment selection?
    3. How may your treatment approach differ based on PD-L1 TPS status?
Related Videos
2 KOLs are featured in this program.
2 KOLs are featured in this program.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
2 KOLs are featured in this series
3 KOLs are featured in this series.